RxDoctor Payments Data

Danny Hernandez, MD

Family Medicine · Allentown, PANPI 1316920390

Payments from drug & device makers

$1,750in general payments, 2019–2025

Across 86 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$311
  • Kowa Pharmaceuticals America, Inc.$233
  • Indivior Inc.$192
  • Braeburn Inc.$188
  • Orexo US, Inc.$160
  • AstraZeneca$141
  • plus $525 from 13 others

What the payments were for

  • Food & beverage$1,750100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,750 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$22,956
Medicare patients
22
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl18$24,211
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl145$22,649
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$7,069
Tresiba Flextouch U-100Insulin Degludec11$5,504
Buprenorphine Hcl71$3,917
Oxycodone Hcl194$3,377
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen28$596
Quetiapine Fumarate24$566
Clonazepam32$457
Omeprazole21$433
Tramadol Hcl17$390
Gabapentin32$318
Zolpidem Tartrate88$295
Chlorthalidone27$293
Tizanidine Hcl21$255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone$192$7,06913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →